~~<i id='4006E26C26'><strike id='4006E26C26'><tt id='4006E26C26'><pre id='4006E26C26'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：entertainment 2025-10-01 19:59:14 Page View：15

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Zepbound, Valneva's vaccine, and more
Next article： Duchenne breakthrough therapy leaves behind pioneering families

focus

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

5:30VivekRamaswamyspeaksduringtheTurningPointActionConferenceatthePalmBeachCountyConventionCenter,Ju

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Flagship, Pfizer team up in deal worth up to $7 billion

PaulBiondiFlagshipPharmagiantPfizeristurningtoventurefirmFlagshipfornewdrugdevelopment,signingadealw